Stay informed in an emergency, set your local ABC radio station in the ABC listen app, and find the frequency on your battery-powered radio. Making sense of emergency warnings It doesn't matter ...
Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Our lead portfolio of NLRP3 inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase 2 development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor ...
“Heading into 2025, Ventyx has established itself as the leader in the field of NLRP3 inhibition having progressed two novel inhibitors, VTX3232 and VTX2735, into Phase 2 trials in neurodegenerative, ...
“Heading into 2025, Ventyx has established itself as the leader in the field of NLRP3 inhibition having progressed two novel inhibitors, VTX3232 and VTX2735, into Phase 2 trials in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback